Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non- small cell lung cancer

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 543-552

  Ichite, Nkechi ^a   Chougule, Mahavir B ^a   Jackson, Tanise ^a   Fulzele, Suniket V ^a   Safe, Stephen ^b   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 BIS (3' INDOYL) 1 (PARA BIPHENYL)METHANE; CASPASE 3; DOCETAXEL; NERVE CELL ADHESION MOLECULE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROCASPASE 3; PROCASPASE 9; PROTEIN BAX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG WEIGHT; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; POLY(ADP-RIBOSE) POLYMERASES; TAXOIDS;

EID: 59449101323     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1558     Document Type: Article

References (38)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
2. Whitehead CM, Earle KA, Fetter J, et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003;2:479-88.
3. McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S. 3,3′- Diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. J Surg Res 2006;132:208-13.
4. Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPAR-γ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006;25:2304-17.
5. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
6. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-80.
7. 2is a ligand for the adipocyte determination factor PPAR-γ. Cell1995;83:803-12.
8. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004;23:100-8.
9. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995;83:813-9.
10. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazoli-dinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ). J Biol Chem 1995;270:12953-6.
11. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res 2000;60:1129-38.
12. Michael LF, Lazar MA, Mendelson CR. Peroxisome proliferator-activated receptor γ1 expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumonocytes. Endocrinology1997;138:3695-703.
13. Qin C, Morrow D, Stewart J, et al. A new class of peroxisome proliferator-activated receptor γ (PPARγ) agonists that inhibit growth of breast cancer cells: 1,1-bis(3′-indolyl)-1-(p-substituted phenyl)methanes. Mol Cancer Ther 2004;3:247-60.
14. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95: 8806-11.
15. ShimadaT, Kojima K.Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 2002;50:658-64.
16. Takahashi N, OkumuraT, Motomura W, FujimotoY, Kawabata I, Kohgo Y. Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999;455:135-9.
17. Kumagai T, IkezoeT, Gui D, et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-γ ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin Cancer Res 2004;10:1508-20.
18. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA. Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2005;24:1412-22.
19. Tsubouchi Y, Sano H, Kawahito Y, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun 2000;270:400-5.
20. Satoh T, Toyoda M, Hoshino H, et al. Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2002;21:2171 -80.
21. Chintharlapalli S, Papineni S, Safe S. 1,1-Bis(3′-indolyl)-1-(p- substituted phenyl) methanes inhibit colon cancer cell and tumor growth through PPARγ-dependent and PPARγ-independent pathways. Mol CancerTher 2006;5:1362-70.
22. Chintharlapalli S, Smith R III, Samudio I, Zhang W, Safe S. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)-methanes induce peroxisome proliferator-activated receptor γ-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. Cancer Res 2004;64:5994-6001.
23. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p- substituted phenyl)methanes: a new class of peroxisome proliferator- activated receptor 7 agonists. Cancer Res 2006; 66:412-8.
24. Chintharlapalli S, Papineni S, Safe S. 1,1-Bis(3′- indolyl)-1-(p-substituted phenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor γ-independent pathways. Mol Pharmacol 2007;71:558-69.
25. Vanderlaag K, Su Y, Frankel AE, et al. 1,1-Bis(3′- indolyl)-1 -(p-substituted phenyl) methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. Breast Cancer ResTreat 2008;109:273-83.
26. Hong J, Samudio I, Liu S, Abdelrahim M, Safe S. Peroxisome proliferator-activated receptor γ-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 2004;145:5774-85.
27. Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S. 3,3′-Diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006;27: 717-28.
28. Hida T, Kozaki K, Ito H, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 2002;8:2443-7.
29. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6: 2006-11.
30. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3:59-70.
31. Shaik MS, Chatterjee A, Jackson T, Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer 2006;118: 396-404.
32. Sweeney CJ, Mehrotra S, Sadaria MR, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 2005;4:1004-12.
33. 2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs 2007;18: 65-78.
34. Menendez JA, del Mar Barbacid M, Montero S, et al. Effects of -γ-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer 2001;37:402-13.
35. Grammes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 2004;5:419-29.
36. Ikezoe T, Miller CW, Kawano S, et al. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res 2001;61:5307-10.
37. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, Jr., Chou TC. Synergistic effects of new chemo-preventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999:59:6178-84.
38. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IκB: NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002;21:6510-9.